Lonza Group AG Reports 19% Sales Growth in H1 2025, Raises Full-Year CDMO Revenue and Margin Forecast

Lonza Group AG reported strong financial results for the first half of 2025, with a revenue of CHF 3.6 billion, marking a 19.0% increase in constant currency terms and a 17.0% rise in actual currency terms compared to the same period in 2024. The core EBITDA reached CHF 1.1 billion, resulting in a robust margin of 29.6%, an improvement of 0.4 percentage points from the first half of 2024. The company’s CDMO (Contract Development and Manufacturing Organization) business contributed significantly to these results, achieving a revenue growth of 23.1% and maintaining a core EBITDA margin of 30.2%. This performance was bolstered by effective operational execution, disciplined cost management, and progress in growth initiatives. The Capsules & Health Ingredients (CHI) segment also performed well with stable revenue and an improved core EBITDA margin of 26.2%, up 1.4 percentage points from the previous year. Looking ahead, Lonza anticipates negative currency effects on revenue and core EBITDA for the full year 2025, estimated at -2.5% to -3.5%, primarily due to the weakening of the US dollar. Despite these challenges, Lonza expects to maintain its margins minimally affected, thanks to natural hedging and financial instruments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lonza Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2173282_de), on July 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)